Clinical trials: Treatment Resistant Depression
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Major Depressive Disorder
Intranasal Ketamine in Treatment-Resistant Depression
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
- Trial name
- NCT01304147
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic…
- Trial name
- TRANSCEND (NCT06423430)
- Testing
- Active-stimulation
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression (TRD)
Maintenance TMS in Treatment Resistant Depression
Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use.
- Trial name
- NCT06682299
- Testing
- Transmagnetic Stimulation, Electroconvulsive Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Austin Messner
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Resistant Major Depression
Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression
The purpose of the study is to investigate the effect of tDCS applied at the anodic left DLPFC of patients with resistant depression compared to patients treated with conventional therapy.
- Trial name
- DEPRESCO (NCT01428804)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Treatment-resistant Bipolar Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment…
- Trial name
- NCT03522545
- Testing
- Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Treatment Resistant Depression
Deep Brain Stimulation for Treatment Resistant Depression
Treatment resistant depression (TRD) is a major global health concern, and there is a crucial need to develop novel effective treatments.
- Trial name
- NCT04009928
- Testing
- Active stimulation of the medial forebrain bundle or subcallosal cingulate
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Unipolar Major Depression
Theta Burst Study Ghent
50 Right-handed antidepressant-free unipolar depressed patients (age 18-65 years) will be treated with in total 20 Theta burst sessions; these will be spread over 4 days.
- Trial name
- TBS Ghent (NCT01832805)
- Testing
- Theta burst stimulation.
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Ghent
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression; Bipolar Disorder
Comparing Different Patterns of rTMS in Major Depression
This trial will compare the trajectories of improvement for three different patterns of twice-daily rTMS in major depression: two daily sessions of dorsomedial prefrontal rTMS delivered at 0 min vs. 30 min vs. 60 min intervals.
- Trial name
- NCT02778035
- Testing
- Dorsomedial prefrontal rTMS
- Where
- 2 sites in Canada
- Volunteers
- 180 people
- Sponsor
- University Health Network, Toronto
Depression - Major Depressive Disorder, Depression Bipolar
Mental Health Mission Mood Disorder Cohort Study
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures…
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Trial name
- NCT07189689
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Oxford
Treatment-resistant Depression, Major Depressive Disorder
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
In the past decades, the prevalence of adolescent depression and suicide increased significantly in Taiwan and worldwide. To date, the suicide mortality is the second mortality cause in the adolescent and young adult population…
- Trial name
- NCT05045378
- Testing
- Ketamine
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Treatment Resistant Depression
Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
The primary goal of the project is to study the effect of Ketamine on cortical neurophysiological function in TRD patients. The proposal employs robust and non-invasive neurophysiological techniques TMS and EEG to investigate the…
- Trial name
- ketamine (NCT02935595)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Health Science Center, Houston
Depressive Disorder, Treatment-Resistant
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory…
- Trial name
- NCT02610712
- Testing
- Ketamine
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurology and Neurosurgery, Mexico
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
- Trial name
- NORLIGHT (NCT07284667)
- Testing
- ACP-211
- Where
- 28 sites in United States
- Volunteers
- 153 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Persistent Depressive Disorder
Feasibility and Effectiveness of a Personalized Inpatient Program for Persistent Depressive Disorder
The major objective of this study is to evaluate a new conceptualized personalized concept of Cognitive Behavioral Analysis System of Psychotherapy (CBASPersonalized) in the treatment of patients with persistent depressive…
- Trial name
- PePsy (NCT03616665)
- Testing
- CBASPersonalized
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Philipps University Marburg